Search Within

Myeloma

Formats
  1. Meeting Abstract (557)
  2. Journal Article (368)
  3. Review (37)
  4. Research Letter (21)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (7)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (1016)
  2. Department of Medicine (1016)
  3. Hematologic Malignancies, Division of (1016)
  4. Hematologic Malignancies Research (669)
  5. Survivorship Research (374)
  6. Sloan Kettering Institute Postdocs (306)

More Groups

People
  1. Alexander Lesokhin (381)
  2. Hani Hassoun (339)
  3. Carl Landgren (336)
  4. Sham Mailankody (297)
  5. Malin Hultcrantz (274)
  6. Heather Landau (249)

More People

Years
  1. 2025 (28)
  2. 2024 (82)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (317)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (86)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (24)

More Publications

Publishers
  1. American Society of Hematology (340)
  2. Elsevier Inc. (160)
  3. American Society of Clinical Oncology (88)
  4. Nature Publishing Group (87)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (1016)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma
    Meeting Abstract

    Patel, K.; Maris, M. B.; Cheson, B. D.; Zonder, J. A.; Lesokhin, A. M.; Von Keudell, G.; Seymour, E. K.; Lin, G. H. Y.; Catalano, T.; Shou, Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Update of the phase 1/2 EVOLVE study (NCT03430011)
    Meeting Abstract

    Mailankody, S.; Jakubowiak, A. J.; Htut, M.; Costa, L. J.; Lee, K.; Ganguly, S.; Kaufman, J. L.; Siegel, D. S. D.; Bensinger, W.; Cota, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment
    Meeting Abstract

    Lee, H. C.; Cohen, A. D.; Chari, A.; Hultcrantz, M.; Nooka, A. K.; Callander, N. S.; Suvannasankha, A.; Badros, A.; Libby, E. N.; Trudel, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone in relapsed/refractory multiple myeloma (RRMM) refractory to pomalidomide and/or an anti-CD38 monoclonal antibody - Primary and subgroup analysis
    Meeting Abstract

    Richardson, P.; Oriol, A.; Larocca, A.; Blade, J.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J.; more...
    American Journal of Hematology (2020)

    Fulltext@MSK | Save
  • A population-based study on serious inpatient bacterial infections in patients with chronic lymphocytic leukemia and their impact on survival
    Journal Article

    Steingrímsson, V.; Gíslason, G. K.; Aspelund, T.; Turesson, I.; Björkholm, M.; Landgren, O.; Kristinsson, S. Y.
    European Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
    Review

    Holstein, S. A.; Howard, A.; Avigan, D.; Bhutani, M.; Cohen, A. D.; Costa, L. J.; Dhodapkar, M. V.; Gay, F.; Gormley, N.; Green, D. J.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Melflufen for relapsed and refractory multiple myeloma
    Review

    Oriol, A.; Larocca, A.; Leleu, X.; Hajek, R.; Hassoun, H.; Rodríguez-Otero, P.; Paner, A.; Schjesvold, F. H.; Gullbo, J.; Richardson, P. G.
    Expert Opinion on Investigational Drugs (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone in relapsed/refractory multiple myeloma (RRMM) refractory to pomalidomide and/or an anti-CD38 monoclonal antibody (mAb) - Final primary analysis
    Meeting Abstract

    Richardson, P. G.; Oriol, A.; Larocca, A.; Bladé, J.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors and immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs), including subgroups with renal impairment (RI) and high-risk (HR) cytogenetics
    Meeting Abstract

    Lonial, S.; Lee, H. C.; Badros, A.; Trudel, S.; Nooka, A. K.; Chari, A.; Abdallah, A. O.; Callander, N. S.; Sborov, D. W.; Suvannasankha, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
    Journal Article

    Rowinsky, E. K.; Paner, A.; Berdeja, J. G.; Paba-Prada, C.; Venugopal, P.; Porkka, K.; Gullbo, J.; Linder, S.; Loskog, A.; Richardson, P. G.; more...
    Investigational New Drugs (2020)

    Fulltext@MSK | Save